176 related articles for article (PubMed ID: 36193036)
21. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
[No Abstract] [Full Text] [Related]
22. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study.
Audic F; de la Banda MGG; Bernoux D; Ramirez-Garcia P; Durigneux J; Barnerias C; Isapof A; Cuisset JM; Cances C; Richelme C; Vuillerot C; Laugel V; Ropars J; Altuzarra C; Espil-Taris C; Walther-Louvier U; Sabouraud P; Chouchane M; Vanhulle C; Trommsdorff V; Pervillé A; Testard H; Lagrue E; Sarret C; Avice AL; Beze-Beyrie P; Pauly V; Quijano-Roy S; Chabrol B; Desguerre I
Orphanet J Rare Dis; 2020 Jun; 15(1):148. PubMed ID: 32532349
[TBL] [Abstract][Full Text] [Related]
23. Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1-3.
Chacko A; Sly PD; Ware RS; Begum N; Deegan S; Thomas N; Gauld LM
Thorax; 2022 Jan; 77(1):40-46. PubMed ID: 33963091
[TBL] [Abstract][Full Text] [Related]
24. Sleep architecture and Nusinersen therapy in children with Spinal Muscular Atrophy type 1.
Verrillo E; Pavone M; Bruni O; Ferri R; Chiarini Testa MB; Cherchi C; D'Amico A; Cutrera R
Sleep Med; 2023 Oct; 110():106-110. PubMed ID: 37572575
[TBL] [Abstract][Full Text] [Related]
25. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
[TBL] [Abstract][Full Text] [Related]
26. Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea.
Shin HJ; Na JH; Lee H; Lee YM
Yonsei Med J; 2023 Dec; 64(12):705-711. PubMed ID: 37992742
[TBL] [Abstract][Full Text] [Related]
27. Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen.
Aragon-Gawinska K; Daron A; Ulinici A; Vanden Brande L; Seferian A; Gidaro T; Scoto M; Deconinck N; Servais L;
Dev Med Child Neurol; 2020 Mar; 62(3):310-314. PubMed ID: 31799720
[TBL] [Abstract][Full Text] [Related]
28. Changes in pNFH Levels in Cerebrospinal Fluid and Motor Evolution after the Loading Dose with Nusinersen in Different Types of Spinal Muscular Atrophy.
Badina M; Bejan GC; Sporea C; Padure L; Mirea A; Leanca MC; Axente M; Grigoras FP; Bejan M; Shelby ES; Neagu E; Ion DA
Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512056
[No Abstract] [Full Text] [Related]
29. A new respiratory scoring system for evaluation of respiratory outcomes in children with spinal muscular atrophy type1 (SMA1) on SMN enhancing drugs.
Edel L; Grime C; Robinson V; Manzur A; Abel F; Munot P; Ridout D; Scoto M; Muntoni F; Chan E
Neuromuscul Disord; 2021 Apr; 31(4):300-309. PubMed ID: 33752934
[TBL] [Abstract][Full Text] [Related]
30. Nusinersen improved respiratory function in spinal muscular atrophy type 2.
Tanaka R; Fukushima F; Motoyama K; Kobayashi C; Izumi I
Pediatr Int; 2021 Aug; 63(8):973-974. PubMed ID: 34245199
[No Abstract] [Full Text] [Related]
31. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
Finkel RS; Mercuri E; Darras BT; Connolly AM; Kuntz NL; Kirschner J; Chiriboga CA; Saito K; Servais L; Tizzano E; Topaloglu H; Tulinius M; Montes J; Glanzman AM; Bishop K; Zhong ZJ; Gheuens S; Bennett CF; Schneider E; Farwell W; De Vivo DC;
N Engl J Med; 2017 Nov; 377(18):1723-1732. PubMed ID: 29091570
[TBL] [Abstract][Full Text] [Related]
32. Sleep and Breathing After Nusinersen Therapy in a Child With Spinal Muscular Atrophy.
Kouri I; Demirel N; Haile DT; Selcen D; Kotagal S
J Clin Neuromuscul Dis; 2020 Dec; 22(2):105-108. PubMed ID: 33214397
[TBL] [Abstract][Full Text] [Related]
33. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
[TBL] [Abstract][Full Text] [Related]
34. Nusinersen treatment of spinal muscular atrophy - a systematic review.
Albrechtsen SS; Born AP; Boesen MS
Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069
[TBL] [Abstract][Full Text] [Related]
35. Nusinersen induces detectable changes in compound motor action potential response in spinal muscular atrophy type 1 patients with severe impairment of motor function.
Ueda Y; Egawa K; Kawamura K; Ochi N; Goto T; Kimura S; Narugami M; Nakakubo S; Nakajima M; Manabe A; Shiraishi H
Brain Dev; 2024 Mar; 46(3):149-153. PubMed ID: 38103972
[TBL] [Abstract][Full Text] [Related]
36. Real-world respiratory and bulbar comorbidities of SMA type 1 children treated with nusinersen: 2-Year single centre Australian experience.
Chen KA; Widger J; Teng A; Fitzgerald DA; D'Silva A; Farrar M
Paediatr Respir Rev; 2021 Sep; 39():54-60. PubMed ID: 33129670
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland.
Tscherter A; Rüsch CT; Baumann D; Enzmann C; Hasselmann O; Jacquier D; Jung HH; Kruijshaar ME; Kuehni CE; Neuwirth C; Stettner GM; Klein A;
Neuromuscul Disord; 2022 May; 32(5):399-409. PubMed ID: 35337708
[TBL] [Abstract][Full Text] [Related]
38. Children and young adults with spinal muscular atrophy treated with nusinersen.
Osredkar D; Jílková M; Butenko T; Loboda T; Golli T; Fuchsová P; Rohlenová M; Haberlova J
Eur J Paediatr Neurol; 2021 Jan; 30():1-8. PubMed ID: 33307321
[TBL] [Abstract][Full Text] [Related]
39. Polysomnography findings in pediatric spinal muscular atrophy types 1-3.
Chacko A; Sly PD; Gauld L
Sleep Med; 2020 Apr; 68():124-130. PubMed ID: 32035302
[TBL] [Abstract][Full Text] [Related]
40. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]